Aurora Investment Counsel Sells 2,145 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aurora Investment Counsel decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,394 shares of the medical equipment provider’s stock after selling 2,145 shares during the quarter. Lantheus makes up approximately 1.4% of Aurora Investment Counsel’s portfolio, making the stock its 11th largest holding. Aurora Investment Counsel’s holdings in Lantheus were worth $2,440,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the period. UMB Bank n.a. grew its position in shares of Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. Fidelis Capital Partners LLC bought a new position in shares of Lantheus in the first quarter worth about $34,000. Nkcfo LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $47,000. Finally, FinTrust Capital Advisors LLC boosted its stake in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Shares of Lantheus stock opened at $109.75 on Tuesday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The firm has a market cap of $7.61 billion, a P/E ratio of 16.76 and a beta of 0.50. The firm’s 50-day simple moving average is $104.36 and its 200-day simple moving average is $86.40.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 earnings per share. As a group, research analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock worth $3,922,001 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on LNTH shares. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JMP Securities cut their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.